Last €48.80 EUR
Change Today -0.17 / -0.35%
Volume 350.5K
As of 11:35 AM 05/20/13 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv (DSM) Snapshot

Open
€48.96
Previous Close
€48.97
Day High
€49.09
Day Low
€48.59
52 Week High
04/25/13 - €50.02
52 Week Low
06/27/12 - €36.42
Market Cap
9.3B
Average Volume 10 Days
619.4K
EPS TTM
€1.50
Shares Outstanding
181.4M
EX-Date
05/7/13
P/E TM
32.5x
Dividend
€1.50
Dividend Yield
3.07%
Current Stock Chart for KONINKLIJKE DSM NV (DSM)

Related News

No related news articles were found.

koninklijke dsm nv (DSM) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv (DSM) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. Its Nutrition segment manufactures food enzymes, cultures, taste ingredients, and other specialties for the food and beverage industries; and offers ingredients for animal and human nutrition and health, such as vitamins, carotenoids, enzymes, cultures, yeast extracts, polyunsaturated fatty acids, premixes, and formulations. The company’s Pharma segment provides custom manufacturing and development services to the pharmaceutical, biopharmaceutical, and crop protection industries; and beta-lactam active pharmaceutical ingredients, such as semi-synthetic penicillins and semi-synthetic cephalosporins, as well as nystatin. Its Performance Materials segment offers engineering thermoplastic solutions; Dyneema, a strong fiber; and resins solutions for paints and coatings, composite materials, and optical fiber coatings. The company’s Polymer Intermediates segment produces caprolactam and acrylonitrile that are raw materials for synthetic fibers and plastics; and ammonium sulfate, sodium cyanide, cyclohexanone, and diaminobutane. Its Innovation Center segment develops materials-based solutions comprising coatings, drug delivery platforms, and a range of biomedical materials for medical device and biopharmaceutical industries; creates solutions for bioconversion of feedstocks for the production of bio-based chemicals and materials; and develops the technologies to enable the production of bioenergy, such as cellulosic biofuels, as well as provides solutions for the development and application of smart coatings. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

23,318 Employees
Last Reported Date: 05/2/13
Founded in 1902

koninklijke dsm nv (DSM) Top Compensated Officers

Chairman of Managing Board, Chief Executive O...
Total Annual Compensation: €1.6M
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €975.0K
Managing Director and Member of Managing Boar...
Total Annual Compensation: €982.0K
Member of the Managing Board and Business Uni...
Total Annual Compensation: €833.0K
Member of the Managing Board
Total Annual Compensation: €966.0K
Compensation as of Fiscal Year 2012.

koninklijke dsm nv (DSM) Key Developments

DSM Approves Appointment of D. De Vreeze as Member of Managing Board

DSM at its annual general meeting held on May 3, 2013, approved appointment of Mr. D. de Vreeze as a member of the Managing Board.

Royal DSM Declares Final Dividend for 2012, Payable on 29 May 2013

Royal DSM Annual General Meeting of Shareholders on 3 May 2013 passed a resolution to declare a dividend for 2012 of EUR 1.50 per ordinary share of EUR 1.50 par value. An interim dividend of EUR 0.48 per ordinary share having been paid on 30 August 2012, the final dividend for 2012 will amount to EUR 1.02 per ordinary share. With the passing of the resolution by the AGM, and in line with DSM's policy to provide a stable and preferably rising dividend, 2012 marks the third consecutive year DSM's dividend has been increased. This final dividend of EUR 1.02 will be paid out in cash or in the form of ordinary shares at the option of the shareholder. Dividend in cash will be paid after deduction of 15% Dutch dividend withholding tax. The ex-dividend date on NYSE Euronext will be 7 May 2013 and the record date will be 9 May 2013. Shareholders have from 10 May until 24 May 2013 to indicate their choice. On 27 May 2013 after the close of trading on NYSE Euronext the number of dividend rights of ordinary shares entitling the holder to one ordinary share will be determined. Delivery of shares or cash payment is 29 May 2013.

DSM Biomedical Reports Earnings Results for the First Quarter of Fiscal 2013

DSM Biomedical reported earnings results for the first quarter of fiscal 2013. For the quarter, the company showed a strong increase in sales versus first quarter 2012, mainly due to the contribution of Kensey Nash (EUR 19 million). All other activities at the Innovation Center were at the same level as in first quarter 2012. EBITDA increased by EUR 11 million compared to first quarter 2012 of which EUR 7 million was due to the contribution of Kensey Nash.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSM:NA €48.80 EUR -0.17

DSM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CF Industries Holdings Inc $191.52 USD +1.00
Kerry Group PLC €44.00 EUR 0.00
Merck KGaA €119.70 EUR +0.55
Solvay SA €113.00 EUR -0.50
Toray Industries Inc ¥747.00 JPY +8.00
View Industry Companies
 

Industry Analysis

DSM

Industry Average

Valuation DSM Industry Range
Price/Earnings 32.9x
Price/Sales 0.9x
Price/Book 1.4x
Price/Cash Flow 31.4x
TEV/Sales 0.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV, please visit www.dsm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.